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Pancreatic b cells, organized in the islets of Langer-
hans, sense glucose and secrete appropriate
amounts of insulin. We have studied the roles of
LKB1, a conserved kinase implicated in the control
of cell polarity and energy metabolism, in adult
b cells. LKB1-deficient b cells show a dramatic
increase in insulin secretion in vivo. Histologically,
LKB1-deficient b cells have striking alterations in
the localization of the nucleus and cilia relative to
blood vessels, suggesting a shift from hepatocyte-
like to columnar polarity. Additionally, LKB1 defi-
ciency causes a 65% increase in b cell volume. We
show that distinct targets of LKB1 mediate these
effects. LKB1 controls b cell size, but not polarity,
via themTOR pathway. Conversely, the precise posi-
tion of the b cell nucleus, but not cell size, is
controlled by the LKB1 target Par1b. Insulin secre-
tion and content are restricted by LKB1, at least in
part, via AMPK. These results expose a molecular
mechanism, orchestrated by LKB1, for the coordi-
nated maintenance of b cell size, form, and function.
INTRODUCTION
On a first approximation, a pancreatic b cell can be described as
a simple device performing two functions: continuous sensing of
blood glucose levels and appropriate secretion of insulin, which
facilitates glucose uptake in peripheral tissues. Although the
molecular machinery responsible for these functions is relatively
well understood (Muoio and Newgard, 2008), the significance of
many characteristic features that might impinge on the quality of
b cell function is far less clear. For example, little is known about
the determinants of size and form in individual b cells and their296 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Iorganization in the islets of Langerhans. Previous studies have
documented thatbcellsare typically organizedas rosettesaround
islet capillaries (Bonner-Weir, 1988), but how this polarized struc-
ture is achieved and maintained and for what purpose remains
poorly understood. Several recent advances show the type of
insights that can be gained from the study of islet and b cell
morphology at the molecular level. Of particular interest is the
discovery that islet capillaries, in addition to serving as carriers
of oxygen and nutrients, enhance insulin secretion and b cell
survival by the provision of extracellular matrix (Nikolova et al.,
2006; Zaret, 2006). A better understanding of b cell and islet
morphologymayalsoaffect thedesignofcellular therapies fordia-
betes. For example, approaches for directed differentiation of
embryonic stem cells into b cells could benefit from taking into
consideration other aspects of b cell biology besides glucose-
stimulated insulin secretion. Here, we uncover a molecular
pathway that controls multiple aspects of b cell morphology and
function, anddefineLKB1asacentral componentof thispathway.
LKB1 encodes a serine-threonine kinase conserved from
worm to man, which is implicated as a central regulator of cell
polarity and energy metabolism in a variety of systems (Alessi
et al., 2006). Although the Caenorhabditis elegans homolog of
LKB1 (Par4) participates in early asymmetric cell divisions of
the embryo, mammalian LKB1 is essential for establishing
neuronal polarity and the growth of axons (Barnes et al., 2007;
Shelly et al., 2007), as well as the generation of polarity in intes-
tinal epithelial cells (Baas et al., 2004) and pancreatic acinar cells
(Hezel et al., 2008). In addition, LKB1 is intimately involved in the
process by which cells sense their energy level (Shaw et al.,
2004b; Woods et al., 2003). These functions of LKB1 are thought
to be achieved by the direct phosphorylation of AMP-activated
protein kinase (AMPK) family of proteins, consisting of 14
members. Of these kinases, SadA-B, Mark1-4, and AMPK
modulate the cytoskeleton, whereas AMPK also serves to alter
energy metabolism in response to fluctuations in cellular
AMP:ATP ratio. How exactly LKB1 integrates extracellular inputs
with intracellular energy charge to control cell polarity is onlync.
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LKB1 Regulates b Cell Function, Polarity, and SizeFigure 1. Expression and Deletion of LKB1 in Adult Islets
(A) Immunofluorescence analysis of LKB1 expression in the adult pancreas. All islet cells express LKB1.
(B) Normal expression of LKB1 in adult pdx1-CreERTM; LKB1lox/lox (PLKB) islets in the absence of tamoxifen.
(C) Complete elimination of LKB1 immunoreactivity in b cells 7 days following tamoxifen injection to 2-month-old mice. Remaining LKB1+ islet cells are insulin,
probably representing alpha and PP cells that do not express pdx1 and therefore do not undergo recombination. All panels, original magnification 4003.partly understood. LKB1 is also an important tumor suppressor
gene (Bardeesy et al., 2002; Ji et al., 2007; Shackelford and
Shaw, 2009). The molecular links between LKB1 and cancer
have not been well defined and may be associated with altered
cell polarity, defective energy sensing, or other processes. An
interesting link between LKB1 and diabetes was uncovered
recently, with the demonstration that liver LKB1 is essential for
the beneficial effects of the AMPK activator and antidiabetes
drug metformin (Shaw et al., 2005). However, the function of
LKB1 in pancreatic b cells has not been examined previously.
By deleting LKB1 in adult b cells in vivo, we show that LKB1
restricts insulincontent, insulinsecretion, andbcell sizeand regu-
lates aspects of b cell polarity. Theseprocesses are controlled via
distinct signalingpathwaysactingdownstreamof LKB1. Thedata
provide a first outline of how the maintenance of b cell size, form,
and function is coordinated at the molecular level.
RESULTS
Expression and Deletion of LKB1 in Adult Islets
of Langerhans
We first characterized LKB1 expression in the adult pancreas. As
shown in Figure 1A, LKB1 is specifically expressed in islets. Cos-Cetaining with insulin revealed that LKB1 is present in the cyto-
plasm of b cells as well as in other hormone-producing cells of
islets. LKB1 was only weakly expressed in the adult exocrine
pancreas (data not shown).
To delete LKB1 in adult islets, we generated pdx1-CreERTM;
LKB1lox/lox mice. In the absence of tamoxifen, these mice were
indistinguishable from wild-type mice, and LKB1 expression
appeared normal (Figure 1B). Injection of tamoxifen (2 doses of
8 mg) resulted in a rapid and efficient deletion of LKB1, evi-
denced by the loss of LKB1 immunoreactivity from b cells within
7 days (Figure 1C). LKB1 expression persisted in insulin-negative
non–b cells at the periphery of islets, reflecting the lack of Pdx1
expression and, hence, Cre-mediated recombination in alpha
and pancreatic polypeptide (PP) cells.
LKB1 Restricts Glucose-Stimulated Insulin
Secretion In Vivo
Pdx1-CreERTM; LKB1lox/lox mice (PLKB mice) had normal fed
and fasting blood glucose levels (Figure 2A). However, a closer
examination revealed abnormal glucose tolerance; PLKB mice
responded to a glucose challenge faster and more efficiently
than did wild-type littermates, as early as 1 week after tamoxifen
injection (Figure 2A and data not shown). Such a behavior can bell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc. 297
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LKB1 Regulates b Cell Function, Polarity, and SizeFigure 2. Effect of LKB1 Deficiency on Glucose Physiology
(A) Fed and fasting blood glucose levels (left) and glucose tolerance (right) in LKB1lox/lox and PLKB mice (n = 11 mice per genotype). Mice were injected with
tamoxifen at 4 weeks of age, and assays were performed 1 week later.
(B) Insulin sensitivity in LKB1lox/lox and PLKB mice (n = 9 mice per genotype). Same mice were used as in (A).
(C) Serum insulin levels 15min after the injection of glucose to LKB1lox/lox and PLKBmice (n = 7mice per genotype). Mice were injected with tamoxifen at 4 weeks
of age, and assay was performed 1 month later. Error bars represent standard deviations. **p < 0.01.explained by either enhanced peripheral sensitivity to insulin or
increased glucose-stimulated insulin secretion. Insulin tolerance
tests showed normal insulin sensitivity in PLKBmice (Figure 2B).
In contrast, following glucose injection, we found higher levels of
insulin in the serum of PLKB mice (Figure 2C). These results
suggest that, in the absence of LKB1, b cells mount an exagger-
ated insulin secretion response to glucose.
Deletion of LKB1 in Adult Islets Increases b Cell Size
and Alters Polarity
Histological analysis of tamoxifen-treated PLKB mice revealed
that mutant b cells were larger than wild-type cells, as early as
1 week after tamoxifen injection. b cell area, defined as the
area surrounded by E-Cadherin immunoreactivity, increased
by 40%, which can be extrapolated to a 65% increase in cell
volume (Figure 3A). In addition, we noticed a striking clustering
of b cell nuclei in mutant islets, which occurred a few days after
deletion of LKB1. Staining for Laminin, an extracellular protein
expressed by islet capillaries (Nikolova et al., 2006), confirmed
previous observations that b cells are organized as rosettes
around blood vessels (Bonner-Weir, 1988). We found that, in
wild-type mice, the b cell nucleus is normally located away
from the center of the rosette, in approximately 70% of the
distance toward the periphery of the rosette (Figure 3B). In
contrast, b cells of PLKBmice, although retaining a rosette orga-
nization, had their nuclei tightly packed around capillaries. Thus,
the presence of LKB1 in b cells is important for appropriate
nuclear positioning within the cell, relative to the blood vessel.
Given this alteration of cell polarity, we examined the position
of primary cilia, another hallmark of cell polarity. Previous studies298 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Iusing immunostaining for acetylated alpha tubulin showed that
b cells contain one cilium per cell (Cano et al., 2004). We found
that, in wild-type mice, cilia are homogenously distributed in
islets and are mostly located in the lateral surfaces of b cells.
In PLKB islets, similar numbers of cilia were present (one cilium
per b cell) but with a striking change in organization. Cilia in PLKB
islets tend to cluster in locations away from the nuclei and away
from capillaries at the center of rosettes (Figure 3C and Figure S1
available online). Finally, we examined the cellular distribution of
the glucose transporter Glut2, reported previously to be located
preferentially in lateral membranes of b cells rich inmicrovilli (Orci
et al., 1989). The intensity of Glut2 immunostaining was reduced
in some faces of b cells, consistent with an alteration of b cell
polarity (Figure S2).
These results show that LKB1 acts to restrict the size of b cells
and is important for the generation and maintenance of normal
polarity of b cells. Moreover, the precise position of nucleus
and monocilia is a previously unappreciated component of
b cell polarity.
LKB1 Regulates b Cell Size via mTOR Pathway
LKB1 is a master kinase, controlling the phosphorylation of 14
downstream kinases of the AMPK family. We postulated that
distinct targets of LKB1 mediate its effects. Using a combination
of Western blot analysis and a survey of microarray expression
data, we found that most LKB1 targets (at least 11 of 14) are
expressed in b cells (Figure S3). We divided these direct targets
to three groups: kinases that were previously implicated in the
control of epithelial cell polarity (Mark1, Mark2, Mark3, and
SadB), a kinase previously implicated in the sensing of cellularnc.
Cell Metabolism
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alpha1), and other kinases with less-defined functions (NUAK1,
NUAK2, MELK, QIK, SIK, and QSK).
Of the LKB1 targets, AMPK stands out as a potential mediator
of b cell size because it is a negative regulator of mTOR
signaling, the major signal transduction pathway controlling
cell size (Bernal-Mizrachi et al., 2001; Corradetti et al., 2004;
Shaw et al., 2004a; Tuttle et al., 2001). We therefore examined
the phosphorylation status and activity of AMPK in LKB1 null
cells. As shown in Figure 4A, AMPK phosphorylation (but not
total levels of AMPK) was significantly reduced in PLKB islets.
In addition, the levels of phoshorylated Acetyl-CoA Carboxylase
(pACC), a direct substrate and hence a marker of AMPK activity,
were dramatically reduced in PLKB islets. These results also
indicate that LKB1 has significant kinase activity in wild-type
islets in the fed condition, consistent with a role in the mainte-
nance of b cell size, form, and function. As an independent
test of this notion, we stained histological sections of pancreata
for phosphorylated AMPK. Because AMPK is known to be phos-
phorylated and activated by LKB1 under energy stress (high
AMP:ATP ratio) (Hawley et al., 2003; Shaw et al., 2004b; Woods
et al., 2003), we compared mice sacrificed in fed and fasting
states. Phosphorylated AMPK can be detected in Islets from
fed mice, and, as expected, islets from fasted mice showed
a dramatic increase in the level of their p-AMPK (Figure S4).
Importantly, islets from PLKB mice had absolutely no p-AMPK
signal. Analysis of mosaic islets containing adjacent wild-type
and mutant b cells also showed that AMPK is phosphorylated
in wild-type, but not in LKB1-deficient, cells in nonfasting, nor-
moglycemic mice. Thus, AMPK is active to some degree and
may serve physiological functions in b cells in vivo even in the
fed state. Such functions are likely to be impaired in PLKB
mice. We further tested whether the mTOR pathway was acti-
vated in PLKB islets, as would be expected if AMPK is inactive
(Shaw et al., 2004a). As shown in Figure 4A, ribosomal protein
S6 (rpS6) and p70S6K were hyperphosphorylated in PLKB islets,
indicating that mTOR pathway was activated. Similarly, immu-
nofluorescence analysis showed a dramatic increase of phos-
phorylated rpS6 in islets of PLKB mice, compared with controls
(Figure S5). These results are consistent with the idea that, in
PLKB mice, b cell size increases because AMPK inactivation
leads to activation of the mTOR pathway. A prediction of this
model is that inhibition of mTOR signaling would reduce the
size of PLKB b cells to a wild-type level. Mice were treated for
2 weeks with the mTOR inhibitor rapamycin, at low doses
used clinically in human patients undergoing immune suppres-
sion (Nir et al., 2007). Phosphorylation of rpS6 was eliminated
in both wild-type and PLKB islets, confirming efficient inhibition
of mTOR (Figure S5). Histological analysis revealed that, in wild-
type mice, this treatment led to a mild 10% decrease in b cell
size (Figure 4B). Strikingly, a much stronger effect was observed
in PLKB b cells, such that rapamycin-treated b cells in wild-type
and mutant mice had the same size. This result supports the
idea that LKB1 restricts b cell size via its effect on mTOR
signaling. To further examine this hypothesis, we determined
b cell size in various mouse mutants carrying alterations in
PI3K-mTOR signaling. As previously reported, mice expressing
a constitutively active version of AKT from the rat insulin
promoter (RIP-AKT) (Tuttle et al., 2001) had remarkably largerCeb cells (Figure 4C). Likewise, mice carrying a b cell-specific dele-
tion of the PTEN tumor suppressor (bPTEN) (Stiles et al., 2006)
also had larger b cells (Figure 4C). As described before, mice
bearing a mutated version of ribosomal protein S6 preventing
its phosphorylation (rpS6 knockin, rpS6KI/KI) had smaller b cells
(Figure 4C) (Ruvinsky et al., 2005), indicating that the effect of
mTOR pathway on b cell size is mediated, at least partially, by
rpS6 phosphorylation. We also tested whether knockdown of
AMPK affects b cell size similarly to the phenotype of LKB1 defi-
ciency. Min6 cells (a murine b cell line) were infected with a lenti-
virus encoding a dominant negative mutant of AMPK alpha1
(D157A) and EGFP, or with a virus encoding dsRED and
EGFP. This mutant AMPK does not have kinase activity, but
competes with native AMPKa for binding to the b and g subunits
of AMPK (da Silva Xavier et al., 2003; Richards et al., 2005;
Woods et al., 2000). Cells overexpressing the dominant negative
mutant had reduced phosphorylation of the AMPK target ACC
(Figure 4D). Flow cytometry analysis showed that cells express-
ing dominant negative AMPK were larger (Figure 4D). Finally, we
examined the size of b cells in mice deficient for Par1b/Mark2/
Emk, another direct LKB1 target (see below). Par1b-deficient
b cells had normal size, indicating that this gene does not affect
cell size (Figure 4C). mTOR activity in Par1b/ islets was
normal, as assessed by immunostaining against phosphorylated
rpS6 (Figure S6). Taken together, these results suggest that, in
normal b cells, LKB1 phosphorylates AMPK, which, by restrict-
ing the mTOR pathway, acts to reduce cell size. As shown
below, this pathway affects specifically b cell size but not
polarity.
Regulation of b Cell Polarity by the LKB1 Target Par1b
Wewished to identify the downstream effectors of LKB1 in regu-
lating b cell polarity. We first examined whether activation of
mTOR pathway could account for the polarity defects observed
in PLKBmice. b cells of rapamycin-treated PLKBmice, although
reduced in size, retained an abnormal nuclear position
(Figure 5A). Similarly, b cells deficient for PTEN, b cells in RIP-
AKT mice, and b cells expressing mutant rpS6 showed normal
positioning of the nucleus relative to blood vessels at the center
of rosettes (Figure 5A). These results suggest that pathways
other than mTOR mediate the effect of LKB1 on b cell polarity.
We then examined the morphology of the pancreas in mice lack-
ing Par1b, an LKB1 target implicated in the generation of polarity
in neurons and hepatocytes (Chen et al., 2006; Cohen et al.,
2004). As described above, Par1b/ islets showed a normal
pattern of phosphorylated rpS6, indicating normal mTOR
signaling (Figure S6). Strikingly, islets in Par1b/ mice had
abnormal clusters of nuclei, unlike the even distribution in wild-
type islets (Figure 5B, bottom). Staining for blood vessels and
b cell nuclei in these mice showed nuclear clustering close to
islet capillaries, partially phenocopying PLKB islets (Figure 5B,
top). The distribution of monocilia in Par1b mutants showed an
intermediate phenotype between wild-type and PLKB mice
(data not shown). In support of a direct link between LKB1 and
Par1b in b cells, the phosphorylation of Mark proteins was
reduced in PLKB islets (Figure 5C). These results provide genetic
evidence that LKB1 controls the polarity, but not the size, of
b cells via Par1b. The milder phenotype of Par1b/ islets,
compared with PLKB islets, suggests that additional LKB1ll Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc. 299
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LKB1 Regulates b Cell Function, Polarity, and SizeFigure 3. LKB1 Deficiency Affects b Cell Size and Polarity
(A) Increased b cell size in LKB1-deficient mice, 3 months after the administration of tamoxifen to 6-week-old mice. Red, E-Cadherin; green, nuclei. Note also the
abnormal clustering of nuclei around capillaries (yellow, autofluorescence of red blood cells). Islets are marked with dashed lines. Original magnification, 6003.
Right, quantification of cell size. Top panel, distribution of islet cell sizes calculated from E-Cadherin immunostaining on paraffin sections. Each curve represents
onemouse. All 6 mice depicted were littermates. Lower panel, FACS plot of dissociated islets from LKB1lox/lox and PLKBmice. Blue, LKB1lox/lox; red, PLKB. Right
shift of mutant cells in both assays represents an increase in average cell size. PLKB = Pdx1-CreER; LKB1 lox/lox.300 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc.
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b cell polarity. LKB1 targets expressed in b cells and associated
with cell polarity such as Mark1, Mark3, SAD-B, and AMPK are
likely to participate in this process.
The Role of LKB1 in Insulin Secretion
To determine more rigorously the direct response of PLKB pan-
creata to glucose while preserving islet morphology, we
measured insulin secretion in perfused pancreata. As shown in
Figure 6A, perfused PLKB pancreata secreted more insulin in
response to glucose, compared with wild-type littermates.
Although the magnitude of the response was dramatically
higher, the kinetics of insulin secretion was normal, as was the
presence of a first and second phase of insulin secretion.
Notably, PLKB pancreata did not secrete more insulin under
basal (low) glucose levels. Increased insulin secretion in vivo
could potentially be the result of increased b cell mass or insulin
content. Morphometric analysis of b cell mass revealed only
a small increase in PLKB mice, compared with controls (37%
or less, depending on calculation method), which is unlikely to
account for the dramatic effect seen in the perfusion experi-
ments (Figure S7). Furthermore, pancreatic insulin content did
not differ between wild-type and PLKB mice, in either fed or
fasted states (Figure S7). An alternative explanation for
enhanced insulin secretion in PLKB mice could be the increased
size of individual b cells (Pende et al., 2000). To test this possi-
bility, we treated mice with low doses of rapamycin for 2 weeks
and then measured insulin secretion in perfused pancreata.
Rapamycin treatment (at doses that normalize b cell size and
eliminate phosphorylation of rpS6; Figure 4 and Figure S5)
reduced the peak values of insulin secretion in both wild-type
and PLKB mice, proving that the drug was active (Figure 6A).
However, it did not prevent oversecretion of insulin in perfused
pancreata of PLKB mice. These results suggest that enhanced
insulin secretion in PLKB mice is at least partially independent
of increased b cell size and hyperactivation of the mTOR
pathway. Analysis of insulin secretion and glucose tolerance in
Par1b mutant mice revealed no significant alteration, compared
with wild-type mice (Figures 6B and 6C). To further study the
effects of LKB1 on insulin secretion, we examined cultured islets
prepared from PLKB mice. Glucose stimulation of mutant islets
led to a modest increase in insulin secretion, compared with
islets from LKB1lox/lox littermates (Figure 6D). However, the
magnitude of the response was small and did not approach
the observed phenotype in vivo. Moreover, in Min6 cells ex-
pressing a dominant negative mutant of LKB1 (Figure S8), we
could not detect a significant increase in glucose-stimulated
insulin secretion, compared with cells expressing wild-type
LKB1 (Figure 6E). These results suggest that LKB1 is unlikely
to affect directly acute stimulus-secretion coupling. Interest-
ingly, we observed a significant increase in insulin content inCeMin6 cells expressing dominant negative LKB1 (Figure 6F). To
begin the analysis of potential downstream mediators of the
effect of LKB1 on b cell function, we examined Min6 cells that
express dominant negative AMPK (described in Figure 4). In
response to high glucose, we could not observe a significant
increase in insulin secretion relative to control cells (Figure 6G).
However, Min6 cells overexpressing dominant negative AMPK
contained more insulin per protein than did control cells, similar
to cells expressing dominant negative LKB1 (Figure 6H). These
results suggest that LKB1, while restricting insulin secretion
in vivo via unknown mechanisms, restricts insulin content
in vitro by activating AMPK and potentially limiting biosynthetic
processes.
DISCUSSION
LKB1 and b Cell Polarity
b cells bear many features of epithelial cells: they express
E-Cadherin, are asymmetrically exposed to endothelial cell-
derived basement membrane (Bonner-Weir, 1988; Nikolova
et al., 2006), and concentrate the glucose transporter Glut2 in
microvilli present in lateral surfaces (Orci et al., 1989). Physiolog-
ically, real-time imaging of isolated islets showed that insulin is
preferentially secreted to the lateral surfaces of b cells, away
from blood vessels (Takahashi et al., 2002). Despite these
data, b cells are normally not conceived as polarized epithelium,
because they do not face the outside world, do not have a visible
lumen, and superficially appear as symmetric spheres.
The data presented here expose novel features of b cell
polarity and provide a molecular mechanism for the generation
and maintenance of b cell morphology. We observed that, in
wild-type b cells, which are organized as rosettes around islet
capillaries (Bonner-Weir, 1988), the nucleus is positioned at
approximately 70% of the distance between the center of the
rosette and the opposing b cell membrane. Additionally, mono-
cilia localize at the lateral surfaces of b cells. Following acute
deletion of LKB1, b cells undergo dramatic changes in their intra-
cellular organization relative to blood vessels: the nucleus is
relocated toward the intrarosette capillary, and the cilium shifts
to the opposite pole of the cell. This phenotype is, in part,
mimicked by the absence of the LKB1 target Par1b. In contrast,
mutants in the PI3K-AKT-mTOR-rpS6 pathway do not show
altered polarity of b cells.
What is the significance of these effects? Previous studies in
cell lines showed that Par1b shifts epithelial cells from a
‘‘columnar’’ phenotype, characterized by an apical lumen, to
‘‘hepatic-like’’ polarity where the lumen is lateral (in the case of
hepatocytes, bile canaliculi) (Cohen et al., 2004; Cohen et al.,
2007). b cells were not previously assigned any of these epithelial
properties. We propose that b cells should be viewed as hepato-
cyte-like epithelial elements with a structural organization that is(B) Altered position of the b cell nucleus versus islet capillaries in PLKB mice. In both strains, b cells are organized as rosettes around capillaries (white arrows).
In PLKB b cells, nuclei shift toward the center of rosettes. Red, E-Cadherin; blue, Laminin; green, nuclei. Right panels, quantification of distance of b cell nuclei
from the center of rosettes (0 = center of rosette, 1 = farthest b cell membrane). Top, each bar represents nuclei from an individual rosette. Bottom, a graphic
summary of data from 7 rosettes taken from 2 mice of each genotype. Blue, LKB1lox/lox; red, PLKB. p < 0.01. Analysis was performed on same mice as in (A).
(C) Altered distribution of monocilia in PLKB islets. In LKB1lox/lox islets, cilia are evenly spread and are usually located on lateral surfaces. In PLKB islets, cilia
(arrowheads) are clustered in positions distant from the center of rosettes (arrows). Red, acetylated alpha tubulin; blue, Glut2; green, nuclei. Original magnifica-
tion, 6003. Analysis was performed on same mice as in (A). Error bars denote standard deviations.ll Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc. 301
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(A) Increased activity of mTOR pathway in islets isolated from PLKB mice. Western blots show decreased LKB1, decreased phosphorylation of AMPK and its
target ACC, and increased phosphorylation of rpS6 and P70S6K.
(B) Low dose of rapamycin for 2 weeks reduces b cell size and eliminates the difference between LKB1lox/lox and PLKB b cells. Mice were injected with tamoxifen
at 5 weeks of age and sacrificed 3 weeks later (n = 2–3 mice per group).
(C) Genetic alterations in PI3K signaling pathway, but not Par1b deficiency, affect b cell size. For eachmutant or transgenic, a coprocessed littermate is shown on
the left. In (B) and (C), red is E-cadherin, and green is nuclei. Cell size was calculated from the circumference of individual cells. In the graphs, blue is wild-type, and
red is transgenic or mutant. Original magnification in (B) and (C), 6003.
(D) Left, infection of Min6 cells with a lentivirus containing a dominant negative (DN) AMPK construct results in increased cell size, compared with cells infected
with an EGFP-containing virus alone, 3 days after infection. Forward-scatter FACS plot of infected (EGFP+) and uninfected cells. Right, decreased phosphory-
lation of ACC in Min6 cells overexpressing DN AMPK. Metformin was added in the last 12 hr to maximize ACC phosphorylation.shaped and maintained by LKB1/Par1b (see model, Figure 7A).
The phenotype of PLKB and Par1b mutants is thus interpreted
as a shift toward columnar polarity, perhaps representing a
default state for these cells. Several observations are consistent
with this idea. In normal b cells, hepatic-like polarity is mani-
fested in the presence of lateral microvilli (Orci et al., 1989), the
localization of cilia in these membrane domains (Figure 3C and302 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier IFigure S1), and the preferred lateral secretion of insulin (Takaha-
shi et al., 2002), even though secretion is not toward the outside
world. The shift to columnar morphology in PLKB b cells is sug-
gested by the repositioning of the nucleus toward the ECM
(which should be considered ‘‘basal’’) and the shift of cilia from
lateral membranes to the cell surface opposing the ECM (which
should be considered ‘‘apical’’). Finally, reducedGlut2 staining innc.
Cell Metabolism
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lateral microvilli. Interestingly, LKB1 was shown to promote the
formation of microvilli in intestinal cells (Baas et al., 2004). In
addition, a recent study found a role for LKB1 in the specific
apical trafficking of a fuel transporter in Drosophila (Filippi and
Alessi, 2008; Jang et al., 2008).
Figure 5. b Cell Polarity Is Altered in Par1b-Deficient Mice, but Not in PI3K Pathway Mutants
(A) Images of islets from several mutant strains, highlighting rosettes of b cells surrounding capillaries. The position of the nucleus in b cells (right panels) was
determined relative to the center of rosettes. Red, E-Cadherin; blue, Laminin; green, nuclei. White lines denote rosettes. Blue, wild-type; red, mutant or trans-
genic. Original magnification, 6003. Analysis was performed on the same mice as in Figure 4.
(B) Nuclei are shifted to the center of rosettes in Par1b/ islets. Top, immunofluorescent image (magnification 6003) of representative rosettes from wild-type
and Par1b/ islets, and quantification. Bottom, hematoxylin and eosin staining (4003 magnification) showing abnormal distribution of nuclei in Par1b mutant
islets.
(C) Reduced phosphorylation of Mark proteins in lysates from PLKB islets, compared with control LKB1lox/lox islets. The upper band represents phosphorylated
Mark3, lower band represents Mark2/Par1b. Error bars denote standard deviations.Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc. 303
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LKB1 Regulates b Cell Function, Polarity, and SizeFigure 6. Mechanism of LKB1-Controlled b Cell Function
(A) Insulin secretion in perfused pancreata, and the effect of rapamycin. Glucose was infused at 2.8 mM (G2.8) or 16.7 mM (G16.7) at the indicated times. Where
indicated, mice were treated with rapamycin for 2 weeks prior to perfusion as described in Experimental Procedures. Data represent the mean ± SE of 4–6 mice.
Mice were injected with tamoxifen at 4 weeks of age, and the assay was performed 2–3 months later. PLKB versus wild-type (no rapamycin), all time points304 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc.
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remains to be elucidated. It is likely that modulation of the cyto-
skeleton by Par1b and its homologs (Cohen et al., 2004), and by
AMPK (Hardie, 2007; Lee et al., 2007; Mirouse et al., 2007), are
involved. Likewise, the nature of signals upstream to LKB1 is still
unclear.
Our data also reveal a novel link between LKB1 andmonocilia.
Although LKB1 is not essential for ciliogenesis, it had an impact
on intracellular cilia positioning. The data suggest that the effects
of LKB1 on cilia are related to the regulation of cell polarity and
are mediated by the Par proteins. We propose that the weaker
cilia phenotype seen in Par1b/ b cells relative to PLKB1 b cells
reflects the redundant participation of Par1 homologs (e.g.,
Mark1 and Mark3) downstream of LKB1. Given the emerging
role of cilia as subcellular signaling centers (Singla and Reiter,
2006), it will be interesting to examine cilia in other models
of LKB1-deficiency, in particular human patients with Peutz-
Jeghers syndrome.
The physiological significance of proper b cell polarity remains
unclear because of the pleiotropic phenotype LKB1 deficiency.
To fully understand the impact of b cell polarity on function
(i.e., insulin secretion), in vivo analysis of mutants defective
specifically in b cell polarity will be required. Analysis of Par1b
mutants (which recapitulate only partially the polarity defect of
PLKB islets) is difficult owing to increased peripheral insulin
sensitivity (Hurov et al., 2007). Nonetheless, our studies of
Par1b/ mice revealed no obvious change in insulin secretion
in vivo (Figure 6B). It will also be important to examine the results
of acute b cell-specific (as opposed to constitutive global) dele-
tion of Par1b and other Mark genes.
LKB1 and b Cell Size
We find that, independently of its effect on b cell polarity, LKB1
acts to restrict the size of b cells. This activity is likely transduced
via phosphorylation of AMPK and, consequently, the downregu-
lation of the mTOR pathway (see model, Figure 7B). To the best
of our knowledge, LKB1 has not previously been implicated in
the regulation of cell size, although the regulation of mTOR
signaling by LKB1-AMPK-TSC is well established (Corradetti
et al., 2004; Inoki et al., 2003; Shaw et al., 2004a). Because
AMPK is a major sensor for cellular energy stress, this pathway
could serve to match b cell size to its metabolic state. Dynamic
adaptation of b cell size was observed before; for example,
b cells grow 25% in size during pregnancy (Dhawan et al.,
2007) and in some settings of persistent hyperinsulinism (AnlaufCelet al., 2005). We propose that the modulation of cell size in these
cases utilizes the LKB1-AMPK-mTOR-rpS6 axis.
LKB1 and b Cell Function
Our studies suggest that LKB1 affects b cell function via several
independent mechanisms. The minor effect of LKB1 or AMPK
deficiency on insulin secretion in vitro argues against a direct
involvement of LKB1/AMPK in acute stimulus-secretion cou-
pling. In contrast, our data reveal that LKB1, acting via AMPK,
restricts insulin content in vitro. Several previous studies have
shown that AMPK restricts insulin secretion (da Silva Xavier
et al., 2003; Leclerc et al., 2004; Richards et al., 2005), although
the effects of AMPK and metformin on b cell function remain
controversial (Gleason et al., 2007). The higher content of insulin
in Min6 cells expressing dominant negative LKB1 or AMPK
suggests one possible mechanism for the negative regulation
of b cell function by LKB1-AMPK. We speculate that AMPK
activity during fasting (and to a lesser extent, under fed condi-
tions) attenuates biosynthesis in b cells; in cells lacking LKB1
or AMPK activity, the biosynthetic machinery remains active
under all conditions, maintaining higher levels of intracellular
insulin. Physiologically, the LKB1-AMPK axis could coordinate
energy charge with the need to replenish insulin content after
prolonged secretion. How AMPK activity reduces insulin content
remains to be discovered, but a plausible candidate is themTOR
pathway, which is known to be involved in protein synthesis as
well as insulin gene transcription (Dowling et al., 2007; Leibiger
et al., 1998; Reiter et al., 2005). This idea is also consistent
with a previous report that AMPK activity reduces insulin gene
expression (da Silva Xavier et al., 2003).
In sharp contrast to the situation in vitro, our data (Figure 6A
and Figure S7) suggest the existence of other pathways bywhich
LKB1 restricts acute insulin secretion in vivo, independently of
insulin content, cell size, and mTOR signaling. We speculate
that these pathways are linked to the effect of LKB1 on b cell
polarity, islet architecture, and the anatomical relationship of
b cells to blood vessels. More experiments will be required to
define in completion the mechanisms by which LKB1 controls
b cell function. Other targets of LKB1 could also restrict insulin
secretion (Figure 7B). For example, the LKB1 targets SIK2 and
Mark2 were previously shown to phosphorylate and prevent
the nuclear translocation of TORC2, a coactivator of the key
transcription factor CREB (Jansson et al., 2008; Screaton
et al., 2004). CREB activity is thought to be important for
restoring aspects b cell metabolism after secretion, in prepara-
tion for the next meal. In the absence of LKB1 (and inactivity ofbetween 11 and 27 min, p < 0.05. Wild-type treated with rapamycin, only t = 11 min has p < 0.05 compared with untreated wild-type. In PLKB mice, effect of
rapamycin treatment was not significant at any time point. In this panel only, error bars denote standard errors.
(B) Blood glucose levels in Par1b/ mice and wild-type littermates, following the injection of glucose.
(C) Serum insulin levels in Par1b/mice and wild-type littermates, following the injection of glucose. Graphs in (B) and (C) show data from females only. Males
produced more variable results (not shown) with no difference between wild-type and mutants. Error bars in (B) and (C) represent standard deviation. N = 3
wild-type, 4 Par1b/ mice. Mice were 2–4 months old. Differences between wild-type and mutant in (B) and (C) were nonsignificant.
(D) Insulin secretion in response to low and high glucose in cultured PLKB islets.
(E) Insulin secretion in Min6 cells overexpressing wild-type or dominant negative LKB1.
(F) Insulin content in Min6 cells expressing wild-type or dominant negative LKB1 under low and high glucose. Cells were cultured overnight in 2.5 mM glucose,
incubated in low glucose/no serum (KRB medium) for 2 hr, and then transferred to low or high glucose for 2 hr before being harvested for ELISA assay.
(G) Insulin secretion in Min6 cells overexpressing dominant negative AMPK or EGFP control.
(H) Insulin content in Min6 cells expressing EGFP or EGFP plus dominant negative AMPK. Experimental protocol was as in (F). Insulin content and secretion in
(D)–(H) are expressed in ng insulin/mg protein.l Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Inc. 305
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positively affect b cell function. The pathway leading from
LKB1 to insulin secretion could be of therapeutic significance,
because it offers opportunities for pharmacologic enhancement
of insulin secretion in the context of diabetes.
LKB1 and the Maintenance of Cell Polarity
Previous studies have focused on the roles of LKB1 and its
targets in the initiation of cell polarity. The use of a temporally
controlled gene deletion system allowed us to assess the func-
tion of LKB1 in the maintenance of morphological homeostasis.
Our data show that, just like insulin secretion and cell size,
features long recognized as highly plastic, the maintenance of
proper b cell polarity also requires ongoing signaling. Interest-
ingly, the activity of LKB1 is limited to shaping the proper polarity
of b cells, because even in its absence b cells have a clear polar-
ized organization. It remains to be determined how the ‘‘morpho-
logical plasticity’’ of b cells affects their function.
Conclusions
Although proper b cell size, morphology, and the magnitude of
insulin secretion are controlled by distinct molecular pathways,
we identify here LKB1 as a central upstream regulator of all these
cellular properties. It is tempting to suggest that LKB1 integrates
multiple inputs, including extracellular cues and intracellular
energy charge, to mount an optimal cellular response on
a dynamic basis. Testing this idea will require further experi-
Figure 7. Proposed Functions of LKB1 in b Cells
(A) A model of b cell polarity and the role of LKB1 and Mark proteins in shifting
cells from a default state of columnar polarity to hepatic-like polarity, charac-
terized by a lateral lumen. Islet capillaries at the center of rosettes provide
basement membrane proteins and define the basal side of b cells. Blue, base-
ment membrane; green, nuclei; red, cilia.
(B) Proposed pathways for the impact of LKB1 on multiple features of b cells.
Dashed lines represent pathways suggested but not proven by our data.306 Cell Metabolism 10, 296–308, October 7, 2009 ª2009 Elsevier Iments and may open up new perspectives on cellular integration
of information and morphological homeostasis of tissues.
EXPERIMENTAL PROCEDURES
Mice
Strains used in this study were LKB1lox/lox (Hezel et al., 2008), pdx1-CreERTM
(Gu et al., 2002), Par1b/ (Hurov et al., 2007), rpS6KI/KI (Ruvinsky et al., 2005),
and Insulin-AKT (Tuttle et al., 2001). PCR genotyping was performed on DNA
extracted from ear punch biopsies, using conditions as previously described.
Sections of insulin-Cre; PTENlox/lox pancreata were the generous gift of
Bangyan stiles (Stiles et al., 2006). GTT, ITT, and measurements of serum
insulin, pancreatic insulin content, and protein content were performed as
described elsewhere (Nir et al., 2007).
Tamoxifen (Sigma, 20 mg/ml in corn oil) was injected subcutaneously. Two
daily doses of 8 mg were used to achieve near total deletion of LKB1 in b cells.
Rapamycin (0.2 mg/kg) was administered by IP injections every other day. The
joint ethics committee (IACUC) of the Hebrew University and Hadassah
Medical Center approved the study protocol for animal welfare. The Hebrew
University is an AAALAC International accredited institute.
Gene Expression and Analysis
A list of antibodies used is provided in the Supplemental Data. To calculate cell
size on tissue sections, the circumference of E-Cadherin-stained cells was
determined using Image J. Alternatively, we used forward-scatter FACS plots
of dissociated islets, prepared as described elsewhere (Dor et al., 2004;
Weinberg et al., 2007). Nuclear position was calculated using well-defined
rosettes in islets stained for DNA, laminin, and E-cadherin. The distance of
a b cell nucleus from the center of rosette was measured on a scale between
0 (center of rosette) and 1 (b cell membrane farthest from center of rosette).
b cell mass was determined morphometrically as described elsewhere
(Nir et al., 2007). Bioinformatics analysis to determine which LKB1 targets
are expressed in b cells was performed as follows. Microarray data sets avail-
able through EPConDB (Mazzarelli et al., 2007) were searched for wild-type
mouse islet cell samples. Thirty-five assays from seven studies were found
using either Affymetrix or Panc Chip (Kaestner et al., 2003) arrays. For Affyme-
trix-based assays, present/marginal/absent calls from the MAS4/MAS5 soft-
ware were used to determine whether a transcript was expressed. For Panc
Chips, a P (present) call was made if the signal for the gene reporter of interest
was above 90% of the blanks on the array (Mazzarelli et al., 2006). For each of
the 13 genes in the LKB1 target list that were represented on the arrays, P and
A calls were collected for each gene reporter in each assay so that at least
seven independent calls were available. The final summary call was based
on whether there were at least two P calls from independent samples. One
call was defined as M (marginal).
Tissue Culture Experiments
Min6 cells were cultured in 15% FCS and 25 mM glucose. Cells were infected
with lentiviruses containing EGFP and dsRED, or EGFP and a D157A domi-
nant-negative mutant of AMPK alpha (da Silva Xavier et al., 2003; Woods
et al., 2000) (a gift of Rachel Hertz). EGFP+ cells were sorted by flow cytometry.
Alternatively, cells were infected with pBABE-Puro retroviruses expressing
wild-type or a K78I dominant negative mutant of human LKB1 (Shaw et al.,
2004b) (http://www.addgene.org). Insulin secretion assays were performed
as described elsewhere (da Silva Xavier et al., 2003).
Pancreas Perfusion
Perfusion of mouse pancreases was performed as described elsewhere (Miki
et al., 2005). Briefly, Pdx1-CreERTM; LKB1lox/lox and control (LKB1lox/lox) mice
at 12–16 weeks of age were pretreated with intraperitoneal injections of
0.2 mg/kg rapamycin (LC Laboratories Boston, MA) every other day for
14 days. Thirty-two hours after the final rapamycin treatment, mice were fasted
overnight (16 hr). Pancreata were preperfused with KRB buffer containing
2.8 mM glucose for 10 min before sampling. After 10 min sampling with KRB
buffer containing 2.8 mM glucose, glucose concentration was shifted to
16.7 mM for 15 min, and was then brought back to 2.8 mM. The flow rate of
the perfusate was 1 ml/min. Insulin in the perfusate was measured usingnc.
Cell Metabolism
LKB1 Regulates b Cell Function, Polarity, and Sizean ELISA kit (Mesacup Insulin Test) from Medical & Biological Laboratories
Co., Ltd. (Nagoya, Japan).
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures and eight
figures and can be found with this article online at http://www.cell.com/
cell-metabolism/supplemental/S1550-4131(09)00258-7.
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